BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. is poised to enhance its financial stability through a planned private placement aiming to raise CAD $500,000 and a debt settlement initiative to address up to CAD $733,600 in liabilities with common shares issuance. The funds from the private placement are intended for the company’s general working capital, facilitating advancements in its diverse immunotherapy platforms. Both the private placement and debt settlement are set to close by July 31st, 2024, conditional upon regulatory approvals and other customary closing requirements.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
